US · Healthcare · Biotechnology
EPS came in at -0.84 against a street estimate of -0.84 — a beat of 0.0%.
Analysts rate Scholar Rock Holding Corp a strong buy (17 buy, 1 hold, 0 sell out of 18) with an average price target of $70.44.
CONFIDENT Scholar Rock nears FDA apitegromab approval (Sept 30 PDUFA) with two independent manufacturing paths ready. Q2 cash $492M strengthened by $63M ATM proceeds. Pipeline advancing: FSHD Phase II launched, SRK-439 Phase I dosing well. Q2 2026 US on track for Q3 2026 approval; EU dependent on Catalent Indiana inspection classification and second facility integration dialogue. Analysts pressed second facility approval independence (fully qualified), Catalent OAI contingency (can withdraw without delay), and payer prior-auth barriers (60+ days expected). Management confident both paths viable; FDA partnership strong; commercial execution mature. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 14.78% |
| Siren, L.L.C. | 7.86% |
| BlackRock Inc | 7.80% |
| Samsara BioCapital, LLC | 5.66% |
| T. Rowe Price Associates, Inc. | 5.58% |
| Wellington Management Company LLP | 5.52% |
| Orbis Allan Gray Ltd | 4.87% |
| Vanguard Capital Management, LLC | 3.92% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 SCHOLAR ROCK HOLDING CORPORATION - 8-K SUMMARY HEADLINE NUMBERS • Company: Scholar Rock Holding Corporation (Nasdaq: SRRK) • Location: Cambridge, MA | 2026-09-15 |
| Reg FD disclosure · Q3 2026 SCHOLAR ROCK HOLDING CORPORATION - 8-K SUMMARY HEADLINE NUMBERS • Drug Approval Date: September 11, 2026 • Product Name: ISEMBYLD™ (apitegromab-mstn | 2026-09-14 |
| Quarterly report · Q2 2026 SCHOLAR ROCK HOLDING CORPORATION – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $437.1 million in cash and equivalents as of June 30, 20 | 2026-08-06 |
| Company announcement · Q3 2026 SCHOLAR ROCK HOLDING CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Company filed prospectus supplement on August 6, 2026 authorizing up to $200, | 2026-08-06 |
| Results announced · Q3 2026 SCHOLAR ROCK Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net loss of $109.9 million for Q2 2026 (compared to $110.0 million in Q2 2025) • N | 2026-08-06 |
| Shareholder vote results · Q2 2026 SCHOLAR ROCK HOLDING CORPORATION – JUNE 4, 2026 FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 4, 2026 • Total votes cast | 2026-06-05 |
| Quarterly report · Q1 2026 SCHOLAR ROCK HOLDING CORP - Q1 2026 SUMMARY HEADLINE NUMBERS • Cash Position: $430.5 million in cash and cash equivalents as of March 31, 2026 (up f | 2026-05-07 |
| Results announced · Q2 2026 SCHOLAR ROCK Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $480 million as of March 31, 2026 • Market opportunity for apite | 2026-05-07 |
Readable in the app.
| Announcement | Date |
|---|---|
| FDA approves ISEMBYLD for spinal muscular atrophy treatment Scholar Rock Holding Corporation announced on September 11, 2026 that the FDA has approved ISEMBYLD (apitegromab-mstn), a treatment for spinal muscular atrophy (SMA) in adults and children a | 2026-09-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Scholar Rock Holding Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.